- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14:22 | Radiopharm Theranostics erhält Steuergutschrift von 4,5 Millionen Dollar für F&E | 2 | Investing.com Deutsch | ||
| RADIOPHARM THERANOSTICS Aktie jetzt für 0€ handeln | |||||
| 14:00 | Radiopharm Theranostics Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 00:01 | RADIOPHARM THERANOSTICS LIMITED: Radiopharm Receives $4.5M R&D Tax Incentive | - | ASX | ||
| 24.06. | Radiopharm unterzeichnet Liefervertrag mit Cyclotek für Prostatakrebs-Medikament | 1 | Investing.com Deutsch | ||
| 24.06. | Radiopharm Theranostics and Cyclotek Sign Clinical Supply Agreement for 6Tb-KLK3-mAb Phase I Clinical Trial in Australia | 104 | GlobeNewswire (Europe) | RAD 402 preclinical data package complete; demonstrates safety and promising biodistribution profile Ethics approval and Phase 1 clinical trial start in prostate cancer anticipated in 2H 2025 ... ► Artikel lesen | |
| 24.06. | Radiopharm Theranostics Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 24.06. | RADIOPHARM THERANOSTICS LIMITED: RAD and Cyclotek Sign Supply Agreement for 161Tb-KLK3-mAb | - | ASX | ||
| 11.06. | Radiopharm Gets FDA Fast Track Designation For RAD101, To Advance Phase 2 Clinical Trial; Stock Up | 3 | RTTNews | ||
| 11.06. | Radiopharm Theranostics Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 04.06. | Radiopharm Theranostics Doses First Patient in Phase 1 'HEAT' Trial of 177Lu-RAD202 for Treatment of Advanced HER2-Positive Solid Tumors | 96 | GlobeNewswire (Europe) | Phase 11 First-In-Human study designed to assess safety, tolerability, right dose for Phase 2 and early signs of efficacy of 177Lu-RAD202 in individuals with advanced HER2-positive solid tumors Previous... ► Artikel lesen | |
| 02.06. | Radiopharm Theranostics Reports Preclinical Lu177-B7H3-mAb Data Demonstrating Favourable Biodistribution and High Tumour Uptake | 169 | GlobeNewswire (Europe) | Supports plans to advance the RV01 program to first-in-human therapeutic basket study in solid tumour cancers Data completes preclinical package for Investigational New Drug submission in mid-2025... ► Artikel lesen | |
| 30.05. | Radiopharm Theranostics Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 19.05. | Radiopharm Theranostics: ITM and Radiopharm Sign Supply Agreement for n.c.a. Lutetium-177 | 2 | GlobeNewswire (USA) | ||
| 12.05. | Radiopharm Theranostics Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 12.05. | ThinkEquity initiates Radiopharm stock with Buy, $15 target | 1 | Investing.com | ||
| 12.05. | Hot Stocks: Ridley Corporation, Orthocell, Radiopharm | 3 | Finance News Network | ||
| 28.04. | Radiopharm Theranostics Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 17.03. | Radiopharm Theranostics: New RAD202 Data Confirms Positive Tumor Uptake and Favorable Biodistribution | 204 | GlobeNewswire (Europe) | Data presented at European Molecular Imaging Meeting (EMIM 2025) for imaging with 68Ga-RAD202 confirms specific accumulation in the tumor, favorable biodistribution and low uptake in non-target organs... ► Artikel lesen | |
| 17.03. | Radiopharm Theranostics Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 17.03. | Radiopharm has seen breast cancer tumour reductions in first-phase trials | 2 | The Market Herald Australia |
1 2 Weiter >>
32 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| LONGEVITY HEALTH | 5,800 | 0,00 % | Pre-market Movers: Longevity Health, SMX (Security Matters), Brazil Potash, Cyclacel Pharmaceuticals, Presidio Property Trust | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 07.15 A.M. ET).In the Green Longevity Health Holdings, Inc. (XAGE) is up over... ► Artikel lesen | |
| EVOTEC | 7,420 | +1,62 % | Aktienmarkt: Evotec-Aktie tritt auf der Stelle (7,232 €) | Im deutschen Wertpapierhandel ist das Wertpapier von Evotec aktuell unauffällig. Der jüngste Kurs betrug 7,23 Euro. Wenig getan hat sich heute bislang beim Kurs von Evotec. Mit einem Preis von 7,23... ► Artikel lesen | |
| NUVALENT | 82,99 | 0,00 % | Nuvalent, Inc.: Nuvalent Announces Positive Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC | Aligned with FDA on NDA submission strategy for TKI pre-treated patients with advanced ROS1-positive NSCLC and participation in Real-Time Oncology Review; the... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,220 | 0,00 % | Recursion Pharmaceuticals (RXRX) Rallies 8.7% on Hypophosphatasia | ||
| QIAGEN | 41,135 | +0,12 % | Dividendenbekanntmachungen (10.07.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACCENTURE PLC IE00B4BNMY34 1,48 USD 1,2626 EUR AT&T INC US00206R1023 0,2775 USD 0,2367 EUR AZZ INC US0024741045 0,2 USD 0,1706... ► Artikel lesen | |
| PROKIDNEY | 3,395 | 0,00 % | ProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for Rilparencel | FDA confirmed that eGFR slope is an acceptable surrogate endpoint for accelerated approval of rilparencel in patients with CKD and type 2 diabetesFDA also confirmed that the ongoing Phase 3 PROACT... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 31,720 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Positive Topline Phase 1/2 FORTITUDE Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in Del-Brax Treated FSHD Participants | -- Unprecedented data from FORTITUDE dose escalation cohorts for del-brax treated participants, compared to placebo, demonstrate improvement in function, strength and PROs as well as rapid... ► Artikel lesen | |
| COGENT BIOSCIENCES | 11,500 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Closing of Upsized Public Offering of Shares of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares | ||
| BEAM THERAPEUTICS | 19,580 | 0,00 % | Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress | Updated Data from 17 Patients Consistent with Previously Presented Data; All Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to Patients... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 24,370 | 0,00 % | Summit Therapeutics vor Mega-Deal: Aktie +15% | Papiere von Summit Therapeutics legen heute in der Spitze um +15% zu. Vorausgegangen ist ein Bloomberg-Bericht um einen bevorstehenden Mega-Deals mit dem Pharmakonzern AstraZeneca. Laut Bloomberg News... ► Artikel lesen | |
| ADMA BIOLOGICS | 17,980 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update | 1Q 2025 Total Revenue of $114.8 Million (Adjusted Total Revenue(1) of $118.6 Million), a 40% YoY Increase 1Q 2025 GAAP Net Income of $26.9 Million, a 51% YoY Increase 1Q 2025 Adjusted EBITDA(2) of... ► Artikel lesen | |
| BICARA THERAPEUTICS | 10,230 | 0,00 % | Bicara Therapeutics Inc.: Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025 | Median DOR of 21.7 months with 80% of responders achieving a deep response (=80% tumor shrinkage) Depth and durability translating to prolonged OS with median OS of 21.3 months and 2-year OS of 46%... ► Artikel lesen | |
| CARGO THERAPEUTICS | 4,605 | 0,00 % | Concentra throws lifeline to troubled CARGO Therapeutics | ||
| BIONTECH | 94,65 | +0,69 % | BioNTech-Konkurrent Moderna: Aktie mit Kurssprung - was ist da los? | Die Aktie von Moderna hat am Dienstag einen kräftigen Kurssprung hinlegen können. Das Papier ging als Top-Gewinner des Tages im S&P 500 vor Intel und Albemarle aus dem Handel. Moderna notiert nun so... ► Artikel lesen | |
| IMMUNOVANT | 17,490 | 0,00 % | Goldman Sachs nimmt Berichterstattung über Immunovant mit "Neutral"-Rating wieder auf |
RADIOPHARM THERANOSTICS LIMITED ADR gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 4,270 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu RADIOPHARM THERANOSTICS LIMITED ADR finden Sie auf Wallstreet Online.